Micafungin* is a semisynthetic lipopeptide from the echinocandin class of antifungal agents. Micafungin is active against most isolates of the following Candida species such as Candida albicans, Candida glabrata, Candida guiliermondii, Candida krusei, Candida parapsilosis and Candida tropicalis.
Indication: Micafungin is indicated for the treatment of invasive candidiasis like blood stream Candida infections and disseminated candidiasis, esophageal candidiasis and for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and in patients at risk of neutropenia (EU).
Application: Administered by intravenous infusion.
Dosage form |
Lyophilized vials |
|||||
Strength |
50 mg 100 mg |
|||||
Compliance |
No monograph for micafungin vials in either Ph. Eur. or USP available |
|||||
Manufacturing site |
CMO for Xellia Pharmaceuticals ApS |
|||||
Release site |
Xellia Pharmaceuticals ApS |
|||||
Site registered |
US FDA |
|||||
Batch size |
|
|||||
Regulatory documentation |
US dossier |
|||||
Packaging sizes |
|
|||||
Shelf life |
| |||||
Storage conditions |
| |||||
* Product protected by valid patents are not offered for sale in countries where the sale of such product constitutes a patent infringement.
